A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis
The main purpose of this research study is to see if natalizumab (Tysabri ®) is effective in slowing the progression of disability independently of relapse in secondary progressive MS (SPMS). This study will also test blood samples for biomarkers, which are naturally-occurring substances in the body, to try to learn more about how they change in MS and how they might be used to predict a patient’s response to treatment with natalizumab.
Participants will randomly be assigned (like flipping a coin) to receive an IV infusion of either natalizumab or matching placebo randomly assigned in clinic by a study nurse monthly for 96 weeks during the study.
Participation in this study will be approximately 114 weeks (27 months). If you have been diagnosed with a secondary progressive multiple sclerosis (SPMS), are between the ages of 18-58 and are able to come to UCSF for study visits you may be eligible to participate.
For more information, please contact Maria Bahn Tigaoan at .(JavaScript must be enabled to view this email address) with ‘ASCEND study inquiry’ subject line or at (415) 502 7218.
